Preliminary report of the effects of propranolol HCl on the discomfiture caused by niacin.
Subjective discomfort caused by nausea and hot, pruritic skin has been described in patients after ingestion of therapeutic dosages of niacin is shown by this study to be alleviated by propranolol HC1. A dosage of 2 mg, I.V., given incrementally, in a clinical trial of six patients is described. The peripheral vasodilator effects of niacin were attenuated in some subjects but not in others. However, all subjects reported relief of unpleasant symptoms. Serial vital signs were taken and no significant changes were found. It is postulated that propranolol HC1 exerts a calmative effect at the CNS level. In a series that utilized doses of 40 and 80 mg of propranolol HC1 taken orally 30 min prior to the ingestion of 500 or 1000 mg of niacin, a progressive increase in the onset of the niacin flush was observed. It is proposed that as the available plasma level of propranolol HC1 falls, the ratio of niacin to propranolol HC1 increases, exceeding the threshold at which the flush occurs. Both these studies suggest that further work is indicated to establish the possible therapeutic efficacy of propranolol HC1.
D002986:Clinical Trials as Topic; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D009539:Nicotinic Acids / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use*; D011537:Pruritus / Q000139:chemically induced / Q000517:prevention & control*
D009539:Nicotinic Acids; D011433:Propranolol